pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Halda Therapeutics LLC

updated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
HLD-0915
Metastatic Castration-Resistant Prostate Cancer (mCRPC)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Halda Therapeutics LLC jobs →

News

  • From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
    Every ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly anticipated phase 3 data for Moderna and Merck & Co.’s cancer vaccine were leaked…
    fiercebiotech · 18d ago
  • ESMO 2026: J&J delivers ‘immaculate’ early data for prostate cancer drug from Halda
    JNJ-6143, which came from Johnson & Johnson’s $3 billion takeover of Halda Therapeutics in 2025, showed a 75% overall response rate in the Phase 1 readout.
    biospace · 19d ago
  • ESMO: J&J exec says RIPTAC readout is ‘best data we’ve ever seen’ for a prostate cancer drug
    A year after paying over $3 billion for Halda Therapeutics, Johnson & Johnson has unveiled the first data from its shiny new RIPTAC pipeline it believes could sustain its leading role in prostate c…
    fiercebiotech · 20d ago
  • STAT+: Pharmalittle: We’re reading about an FDA review of Moderna’s flu shot, J&J’s focus on cancer, and more
    Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer
    stat · 4mo ago
identifiers
source
globaldata
top tags
Oncology1
mentioned in
4news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?